Market closedNon-fractional

Longboard Pharmaceuticals/LBPH

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Longboard Pharmaceuticals

Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.

Ticker

LBPH

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

La Jolla, United States

Employees

50

LBPH Metrics

BasicAdvanced
$1.2B
Market cap
-
P/E ratio
-$2.19
EPS
1.27
Beta
-
Dividend rate
$1.2B
1.27
31.433
31.2
1.169
1.269
-19.30%
-30.04%
3.94
3.94
-15.94
-14.00%
-20.42%

What the Analysts think about LBPH

Analyst Ratings

Majority rating from 9 analysts.
Buy

LBPH Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$15M
-0.67%
Profit margin
0.00%
NaN%

LBPH Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 13.63%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.65
-$0.55
-$0.62
-$0.42
-
Expected
-$0.60
-$0.70
-$0.60
-$0.49
-$0.44
Surprise
9.11%
-21.87%
3.80%
-13.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Longboard Pharmaceuticals stock?

Longboard Pharmaceuticals (LBPH) has a market cap of $1.2B as of July 05, 2024.

What is the P/E ratio for Longboard Pharmaceuticals stock?

The price to earnings (P/E) ratio for Longboard Pharmaceuticals (LBPH) stock is 0 as of July 05, 2024.

Does Longboard Pharmaceuticals stock pay dividends?

No, Longboard Pharmaceuticals (LBPH) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Longboard Pharmaceuticals dividend payment date?

Longboard Pharmaceuticals (LBPH) stock does not pay dividends to its shareholders.

What is the beta indicator for Longboard Pharmaceuticals?

Longboard Pharmaceuticals (LBPH) has a beta rating of 1.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Longboard Pharmaceuticals stock

Buy or sell Longboard Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing